Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine... see more

NDAQ:PMN - Post Discussion

ProMIS Neurosciences Inc > Management team letting us down
View:
Post by JoeyBoston on Oct 08, 2020 6:37pm

Management team letting us down

Yeah, its becoming clear this management team/Board is letting investors down. They have no clue on how to raise shareholder value - financing, marketing, partnering, etc. But, thats when you get when have scientists, not entrepreneurs, making the key decisions. An expensive lesson learned for me.
Comment by Alex1726 on Oct 08, 2020 8:59pm
They had a deal , Giovinnazo concluded the deal but the board rejected it . Is he unloaded? Probaly. The ones that knows in detail what we don't do sell and that could Goivinnazo and relatives , friends, partners and so on. This is not totally bad because they a deal in hands , the stock can't go down because of a possible clinical trial that will fail,  they never did any clinical ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities